Updated overall survival data from the phase 3 MONALEESA-3 trial demonstrated a sustained benefit with the addition of ribociclib to fulvestrant in patients with hormone receptor–positive, HER2-negative advanced breast cancer, and provide further evidence that this is a feasible approach for frontline therapy in this population.

Immunotherapy Combos, Novel Agents Hold Promise in Recurrent Ovarian Cancer

September 24, 2021

Article

Ritu Salani, MD, MBA, discussed the clinical rationale to evaluate combination strategies with immunotherapy in ovarian cancer, as well as novel agents in clinical development that could further influence the treatment paradigm.

Dr. Salani on the Potential Impact of Ongoing Research in Ovarian Cancer

September 22, 2021

Video

Ritu Salani, MD, MBA, discusses the scope of ongoing research in advanced ovarian cancer.

Giredestrant Induces Greater Ki-67 Suppression Vs Anastrozole in ER+/HER2– Early Breast Cancer

September 21, 2021

Article

Giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results from an interim analysis of the phase 2 coopERA Breast Cancer trial.

Dr. Wainberg on the Need for Continued Enrollment to Clinical Trials in CRC

September 20, 2021

Video

Zev A. Wainberg, MD, discusses the importance of enrolling patients with colorectal cancer to clinical trials, despite the difficulties caused by COVID-19.

Lisberg Discusses the Promise of Datapotamab Deruxtecan in Lung Cancer

September 09, 2021

Podcast

Lisberg discusses the excitement with datopotamab deruxtecan in non–small cell lung cancer and previews anticipated data from the NSCLC cohort of the TROPION-PanTumor01 trial at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.

Ovarian Cancer: Chaired by Sanaz Memarzadeh, MD, PhD

July 28, 2021

Video

GI Experts Discuss Treatment Dosing, Sequencing, and Future Directions in CRC

July 15, 2021

Article

Jaffar A. Ajani, MD, and Zev A. Wainberg, MD, discuss FDA updates regarding the dosing schedule of cetuximab for metastatic colorectal cancer and the value of real-word data on clinical practice patterns in the community when administering this drug.

Wainberg Weighs In on Advances in HER2+ GI Cancers

July 12, 2021

Podcast

Dr. Wainberg discusses factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more.

TheraSphere Proves Highly Effective in HCC

June 03, 2021

Article

Siddharth Padia, MD, explaines TheraSphere’s unique mechanism of action and what its approval means in HCC and beyond.

Moving Beyond Chemotherapy in Metastatic Pancreatic Cancer

April 22, 2021

Article

Zev A. Wainberg, MD, discusses the role of neoadjuvant chemotherapy in resectable pancreatic cancer, emerging approaches in locally advanced disease, the promise of PARP inhibitors in the metastatic setting, and other future research directions of interest.

Dr. Wainberg on Optimal Dosing With Regorafenib in CRC

April 19, 2021

Video

Zev A. Wainberg, MD, discusses optimal dosing with regorafenib in colorectal cancer.